|
1.
|
Stanley M: Pathology and epidemiology of
HPV infection in females. Gynecol Oncol. 117:S5–S10. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lowy DR, Strickland JE and Yuspa SH:
Efficient induction of papillomas by Harvey murine sarcoma-virus.
Clin Res. 34:A7641986.
|
|
3.
|
Joh J, Jenson AB, Proctor M, et al:
Molecular diagnosis of a laboratory mouse papillomavirus (MusPV).
Exp Mol Pathol. 93:416–421. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Mitsouras K, Faulhaber EA, Hui G, et al:
Development of a PCR assay to detect papillomavirus infection in
the snow leopard. BMC Vet Res. 7:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Badulescu F, Crisan A, Badulescu A and
Schenker M: Recent data about the role of human papillomavirus
(HPV) in oncogenesis of head and neck cancer. Rom J Morphol
Embryol. 51:437–440. 2010.PubMed/NCBI
|
|
6.
|
Fakhry C, Westra WH, Cmelak SLA, et al:
Improved survival of patients with human papillomavirus-positive
head and neck squamous cell carcinoma in a prospective clinical
trial. J Natl Cancer Inst. 100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Syrjanen S: Human papillomavirus (HPV) in
head and neck cancer. J Clin Virol. 32:S59–S66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Walden MJ and Aygun N: Head and neck
cancer. Semin Roentgenol. 48:75–86. 2013. View Article : Google Scholar
|
|
9.
|
Forte T, Niu J, Lockwood GA and Bryant HE:
Incidence trends in head and neck cancers and human papillomavirus
(HPV)-associated oropharyngeal cancer in Canada, 1992–2009. Cancer
Causes Control. 23:1343–1348. 2012.
|
|
10.
|
Axell T, Pindborg JJ, Smith CJ and van der
Waal I: Oral white lesions with special reference to precancerous
and tobacco related lesions: conclusions of an international
symposium held in Uppsala, Sweden, May 18–21 1994. J Oral Pathol
Med. 25:49–54. 1996.PubMed/NCBI
|
|
11.
|
Janicek MF and Averette HE: Cervical
cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin.
51:92–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chen YC and Hunter DJ: Molecular
epidemiology of cancer. CA Cancer J Clin. 55:45–54. 2005.
View Article : Google Scholar
|
|
13.
|
De Villiers EM, Fauquet C, Broker TR,
Bernard HU and zur Hausen H: Classification of papillomaviruses.
Virology. 324:17–27. 2004.
|
|
14.
|
Bernard HU, Burk RD, Chen ZG, van
Doorslaer K, zur Hausen H and de Villiers EM: Classification of
papillomaviruses (PVs) based on 189 PV types and proposal of
taxonomic amendments. Virology. 401:70–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Doorbar J, Quint W, Banks L, et al: The
biology and life-cycle of human papillomaviruses. Vaccine.
30:F55–F70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Chen RW, Aaltonen LM and Vaheri A: Human
papillomavirus type 16 in head and neck carcinogenesis. Rev Med
Virol. 15:351–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Pfister H: HPV and skin neoplasia.
Hautarzt. 59:26–30. 2008.(In German).
|
|
18.
|
Steben M and Duarte-Franco E: Human
papillomavirus infection: epidemiology and pathophysiology. Gynecol
Oncol. 107:S2–S5. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Chang KC, Su IJ, Tsai ST, Shieh DB and Jin
YT: Pathological features of betel quid-related oral epithelial
lesions in Taiwan with special emphasis on the tumor progression
and human papillomavirus association. Oncology. 63:362–369. 2002.
View Article : Google Scholar
|
|
20.
|
Kero K, Rautava J, Syrjanen K, Grenman S
and Syrjanen S: Oral mucosa as a reservoir of human papillomavirus:
point prevalence, genotype distribution, and incident infections
among males in a 7-year prospective study. Eur Urol. 62:1063–1070.
2012.
|
|
21.
|
Hong AM, Martin A, Armstrong BK, et al:
Human papillomavirus modifies the prognostic significance of T
stage and possibly N stage in tonsillar cancer. Ann Oncol.
24:215–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Milano MT, Peterson CR, Zhang H, Singh DP
and Chen Y: Second primary lung cancer after head and neck squamous
cell cancer: population-based study of risk factors. Head Neck.
34:1782–1788. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ragin CCR and Taioli E: Survival of
squamous cell carcinoma of the head and neck in relation to human
papillomavirus infection: review and meta-analysis. Int J Cancer.
121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lin KY, Westra WH, Kashima HK, Mounts P
and Wu TC: Coinfection of HPV-11 and HPV-16 in a case of laryngeal
squamous papillomas with severe dysplasia. Laryngoscope.
107:942–947. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Syrjanen KJ, Chang F and Syrjanen SM: HPV
infections in etiology of benign and malignant sinonasal, bronchial
and oesophageal squamous cell lesions. Eurogin 2000: 4th
International Multidisciplinary Congress. Monsonego J: Medimond S R
L: 40128 Bologna; pp. 169–179. 2000
|
|
26.
|
Hoffmann M, Klose N, Gottschlich S, et al:
Detection of human papillomavirus DNA in benign and malignant
sinonasal neoplasms. Cancer Lett. 239:64–70. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Syrjanen S: Human papillomavirus
infections and oral tumors. Med Microbiol Immunol. 192:123–128.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kashima HK, Kessis T, Hruban RH, Wu TC,
Zinreich SJ and Shah KV: Human papilloma virus in sinonasal
papillomas and squamous-cell carcinoma. Laryngoscope. 102:973–976.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Mansell NJ and Bates GJ: The inverted
Schneiderian papilloma: a review and literature report of 43 new
cases. Rhinology. 38:97–101. 2000.PubMed/NCBI
|
|
30.
|
Zandberg DP, Bhargava R, Badin S and
Cullen KJ: The role of human papillomavirus in nongenital cancers.
CA Cancer J Clin. 63:57–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ustav M, Ustav E, Szymanski P and Stenlund
A: Identification of the origin of replication of bovine
papillomavirus and characterization of the viral origin recognition
factor-E1. EMBO J. 10:4321–4329. 1991.PubMed/NCBI
|
|
32.
|
Baker CC, Phelps WC, Lindgren V, Braun MJ,
Gonda MA and Howley PM: Structural and transcriptional analysis of
human papillomavirus type-16 sequences in cervical-carcinoma
cell-lines. J Virol. 61:962–971. 1987.PubMed/NCBI
|
|
33.
|
Bouvard V, Storey A, Pim D and Banks L:
Characterization of the human papillomavirus E2 protein - evidence
of transactivation and transrepression in cervical keratinocytes.
EMBO J. 13:5451–5459. 1994.PubMed/NCBI
|
|
34.
|
Foguel D, Silva JL and de Prat-Gay G:
Characterization of a partially folded monomer of the DNA-binding
domain of human papillomavirus E2 protein obtained at high
pressure. J Biol Chem. 273:9050–9057. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Zur Hausen H: Cervical carcinoma and human
papillomavirus: on the road to preventing a major human cancer. J
Natl Cancer Inst. 93:252–253. 2001.
|
|
36.
|
Barbosa MS, Lowy DR and Schiller JT:
Papillomavirus polypeptide-E6 and polypeptide-E7 are zinc-binding
proteins. J Virol. 63:1404–1407. 1989.PubMed/NCBI
|
|
37.
|
Scheffner M, Werness BA, Huibregtse JM,
Levine AJ and Howley PM: The E6 oncoprotein encoded by human
papillomavirus type-16 and type-18 promotes the degradation of P53.
Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Vega-Pena A, Illades-Aguiar B,
Flores-Alfaro E, Lopez-Bayghen E, Reyes-Maldonado E and
Alarcon-Romero LD: Correlation between KI-67 and telomerase
expression with in situ hybridization for high-risk human
papillomavirus. Arch Biol Sci. 65:81–90. 2013. View Article : Google Scholar
|
|
39.
|
Li DS, Dong BL, Hu ZM, et al: A combined
assay of hTERT and E6 oncoprotein to identify virus-infected
keratinocytes with higher telomerase activity in human
papillomaviruses 16 and 18-related bowenoid papulosis. Am J
Dermatopathol. 34:813–817. 2012. View Article : Google Scholar
|
|
40.
|
Zhao YX, Qi L, Chen F, Zhao Y and Fan CH:
Highly sensitive detection of telomerase activity in tumor cells by
cascade isothermal signal amplification based on three-way junction
and base-stacking hybridization. Biosens Bioelectron. 41:764–770.
2013. View Article : Google Scholar
|
|
41.
|
Wilting SM, Verlaat W, Jaspers A, et al:
Methylation-mediated transcriptional repression of microRNAs during
cervical carcinogenesis. Epigenetics. 8:220–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman
SM and Tsao AS: Meta-analysis of the impact of human papillomavirus
(HPV) on cancer risk and overall survival in head and neck squamous
cell carcinomas (HNSCC). Head Neck Oncol. 2:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Dyson N, Howley PM, Munger K and Harlow E:
The human papilloma virus-16 E7-oncoprotein is able to bind to the
retinoblastoma gene-product. Science. 243:934–937. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Strati K, Pitot HC and Lambert PF:
Identification of biomarkers that distinguish human papillomavirus
(HPV)-positive versus HPV-negative head and neck cancers in a mouse
model. Proc Natl Acad Sci USA. 103:14152–14157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Smith EM, Pawlita M, Rubenstein LM, Haugen
TH, Hamsikova E and Turek LP: Risk factors and survival by HPV-16
E6 and E7 antibody status in human papillomavirus positive head and
neck cancer. Int J Cancer. 127:111–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Doorbar J and Gallimore PH: Identification
of proteins encoded by the L1 and L2 open reading frames of human
papillomavirus 1a. J Virol. 61:2793–2799. 1987.PubMed/NCBI
|
|
47.
|
Rose BR, Thompson CH, Tattersall MH,
O’Brien CJ and Cossart YE: Squamous carcinoma of the head and neck:
molecular mechanisms and potential biomarkers. Aust N Z J Surg.
70:601–606. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Wiest T, Schwarz E, Enders C,
Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7
gene expression in head and neck cancers with unaltered p53 status
and perturbed pRb cell cycle control. Oncogene. 21:1510–1517. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Bedell MA, Jones KH and Laimins LA: The
E6-E7 region of human papillomavirus type-18 is sufficient for
transformation of NIH-3T3 and RAT-1 cells. J Virol. 61:3635–3640.
1987.PubMed/NCBI
|
|
50.
|
Choo KB, Pan CC and Han SH: Integration of
human papillomavirus type-16 into cellular DNA of
cervical-carcinoma-preferential deletion of the E2 gene and
invariable retention of the long control region and the E6/E7 open
reading frames. Virology. 161:259–261. 1987. View Article : Google Scholar
|
|
51.
|
Huibregtse JM, Scheffner M and Howley PM:
Cloning and expression of the cDNA for E6-AP, a protein that
mediates the interaction of the human papillomavirus E6 oncoprotein
with P53. Mol Cell Biol. 13:775–784. 1993.PubMed/NCBI
|
|
52.
|
Chellappan S, Kraus VB, Kroger B, et al:
Adenovirus-E1A, simian virus-40 tumor-antigen, and human
papillomavirus-E7 protein share the capacity to disrupt the
interaction between transcription factor-E2F and the retinoblastoma
gene-product. Proc Natl Acad Sci USA. 89:4549–4553. 1992.
View Article : Google Scholar
|
|
53.
|
Cobrinik D, Dowdy SF, Hinds PW, Mittnacht
S and Weinberg RA: The retinoblastoma protein and the regulation of
cell cycling. Trends Biochem Sci. 17:312–315. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Nevins JR: E2F - a link between the Rb
tumor suppressor protein and viral oncoproteins. Science.
258:424–429. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Gillison ML, Koch WM, Capone RB, et al:
Evidence for a causal association between human papillomavirus and
a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
May P and May E: Twenty years of p53
research: structural and functional aspects of the p53 protein.
Oncogene. 18:7621–7636. 1999.PubMed/NCBI
|
|
57.
|
Yu ZK, Geyer RK and Maki CG:
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.
Oncogene. 19:5892–5897. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Huibregtse JM, Scheffner M and Howley PM:
A cellular protein mediates association of P53 with the E6
oncoprotein of human papillomavirus type-16 or type-18. EMBO J.
10:4129–4135. 1991.PubMed/NCBI
|
|
60.
|
Chen JJ, Hong YH, Rustamzadeh E, Baleja JD
and Androphy EJ: Identification of an alpha helical motif
sufficient for association with papillomavirus E6. J Biol Chem.
273:13537–13544. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Elston RC, Napthine S and Doorbar J: The
identification of a conserved binding motif within human
papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J Gen
Virol. 79:371–374. 1998.PubMed/NCBI
|
|
62.
|
Huibregtse JM, Scheffner M and Howley PM:
Localization of the E6-AP regions that direct human papillomavirus
E6 binding, association with P53, and ubiquitination of associated
proteins. Mol Cell Biol. 13:4918–4927. 1993.PubMed/NCBI
|
|
63.
|
Yu Y, Yang AM, Hu SK, Zhang JH and Yan H:
Significance of human papillomavirus 16/18 infection in association
with p53 mutation in lung carcinomas. Clin Respir J. 7:27–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Katori H, Nozawa A and Tsukuda M:
Relationship between p21 and p53 expression, human papilloma virus
infection and malignant transformation in sinonasal-inverted
papilloma. Clin Oncol. 18:300–305. 2006. View Article : Google Scholar
|
|
65.
|
Fujita S, Senba M, Kumatori A, Hayashi T,
Ikeda T and Toriyama K: Human papillomavirus infection in oral
verrucous carcinoma: genotyping analysis and inverse correlation
with p53 expression. Pathobiology. 75:257–264. 2008. View Article : Google Scholar
|
|
66.
|
Reschner A, Bontems S, Le Gac S, et al:
Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit
the growth of cervical cancer cells under illumination by a
mechanism involving p53. Gene Ther. 20:435–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Togtema M, Pichardo S, Jackson R, Lambert
PF, Curiel L and Zehbe I: Sonoporation delivery of monoclonal
antibodies against human papillomavirus 16 E6 restores p53
expression in transformed cervical keratinocytes. PLoS One. 7:1–12.
2012. View Article : Google Scholar
|
|
68.
|
Habbous S, Pang V, Eng L, et al: p53
Arg72Pro polymorphism, HPV status and initiation, progression, and
development of cervical cancer: a systematic review and
meta-analysis. Clin Cancer Res. 18:6407–6415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Chen SP, Hsu NY, Wu JY, et al: Association
of p53 codon 72 genotypes and clinical outcome in human
papillomavirus-infected lung cancer patients. Ann Thorac Surg.
95:1196–1203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Grossman SR and Laimins LA: E6-protein of
human papillomavirus type-18 binds zinc. Oncogene. 4:1089–1093.
1989.PubMed/NCBI
|
|
71.
|
Kanda T, Watanabe S, Zanma S, Sato H,
Furuno A and Yoshiike K: Human papillomavirus type-16 E6 proteins
with glycine substitution for cysteine in the metal-binding motif.
Virology. 185:536–543. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Beerheide W, Bernard HU, Tan YJ, Ganesan
A, Rice WG and Ting AE: Potential drugs against cervical cancer:
zinc-ejecting inhibitors of the human papillomavirus type 16 E6
oncoprotein. J Natl Cancer Inst. 91:1211–1220. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Chan SY, Delius H, Halpern AL and Bernard
HU: Analysis of genomic sequences of 95 papillomavirus types -
uniting typing, phylogeny, and taxonomy. J Virol. 69:3074–3083.
1995.PubMed/NCBI
|
|
74.
|
Ullman CG, Haris PI, Galloway DA, Emery VC
and Perkins SJ: Predicted alpha-helix/beta-sheet secondary
structures for the zinc-binding motifs of human papillomavirus E7
and E6 proteins by consensus prediction averaging and spectroscopic
studies of E7. Biochem J. 319:229–239. 1996.
|
|
75.
|
Griffin H, Elston R, Jackson D, et al:
Inhibition of papillomavirus protein function in cervical cancer
cells by intrabody targeting. J Mol Biol. 355:360–378. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Zimmermann H, Degenkolbe R, Bernard HU and
O’Connor MJ: The human papillomavirus type 16 E6 oncoprotein can
down-regulate p53 activity by targeting the transcriptional
coactivator CBP/p300. J Virol. 73:6209–6219. 1999.PubMed/NCBI
|
|
77.
|
Jong JE, Jeong KW, Shin H, Hwang LR, Lee D
and Seo T: Human papillomavirus type 16 E6 protein inhibits DNA
fragmentation via interaction with DNA fragmentation factor 40.
Cancer Lett. 324:109–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Mavromatis KO, Jones DL, Mukherjee R, Yee
C, Grace M and Munger K: The carboxyl-terminal zinc-binding domain
of the human papillomavirus E7 protein can be functionally replaced
by the homologous sequences of the E6 protein. Virus Res.
52:109–118. 1997. View Article : Google Scholar
|
|
79.
|
Wayengera M: Zinc finger arrays binding
human papillomavirus types 16 and 18 genomic DNA: precursors of
gene-therapeutics for in-situ reversal of associated cervical
neoplasia. Theor Biol Med Model. 9:1–13. 2012. View Article : Google Scholar
|
|
80.
|
Cannavo I, Benchetrit M, Loubatier C,
Michel G, Lemichez E and Giordanengo V: Characterization of a
cluster of oncogenic mutations in E6 of a human papillomavirus 83
variant isolated from a high-grade squamous intraepithelial lesion.
J Gen Virol. 92:2428–2436. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81.
|
Avvakumov N, Torchia J and Mymryk JS:
Interaction of the HPV E7 proteins with the pCAF acetyltransferase.
Oncogene. 22:3833–3841. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
82.
|
Mino T, Mori T, Aoyama Y and Sera T:
Cell-permeable artificial zinc-finger proteins as potent antiviral
drugs for human papillomaviruses. Arch Virol. 153:1291–1298. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
83.
|
Olthof NC, Straetmans J, Snoeck R,
Ramaekers FCS, Kremer B and Speel EJM: Next-generation treatment
strategies for human papillomavirus-related head and neck squamous
cell carcinoma: where do we go? Rev Med Virol. 22:88–105. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
84.
|
Garcia-Vallve S, Alonso A and Bravo IG:
Papillomaviruses: different genes have different histories. Trends
Microbiol. 13:514–521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
85.
|
Van Doorslaer K, Sidi A, Zanier K, et al:
Identification of unusual E6 and E7 proteins within avian
papillomaviruses: cellular localization, biophysical
characterization, and phylogenetic analysis. J Virol. 83:8759–8770.
2009.
|
|
86.
|
Cole ST and Danos O: Nucleotide-sequence
and comparative-analysis of the human papillomavirus type 18
genome. Phylogeny of papillomaviruses and repeated structure of the
E6 and E7 gene products. J Mol Biol. 193:599–608. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
87.
|
Gammoh N, Grm HS, Massimi P and Banks L:
Regulation of human papillomavirus type 16 E7 activity through
direct protein interaction with the E2 transcriptional activator. J
Virol. 80:1787–1797. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
88.
|
Ruttkay-Nedecky B, Nejdl L, Gumulec J, et
al: The role of metallothionein in oxidative stress. Int J Mol Sci.
14:6044–6066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
89.
|
Krizkova S, Ryvolova M, Hrabeta J, et al:
Metallothioneins and zinc in cancer diagnosis and therapy. Drug
Metab Rev. 44:287–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90.
|
Eckschlager T, Adam V, Hrabeta J, Figova K
and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci.
10:360–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91.
|
Krizkova S, Fabrik I, Adam V, Hrabeta J,
Eckschlager T and Kizek R: Metallothionein - a promising tool for
cancer diagnostics. Bratisl Lek Listy. 110:93–97. 2009.PubMed/NCBI
|
|
92.
|
Babula P, Masarik M, Adam V, et al:
Mammalians’ metallothioneins and their properties and functions.
Metallomics. 4:739–750. 2012.
|
|
93.
|
Krejcova L, Fabrik I, Hynek D, et al:
Metallothionein electrochemically determined using Brdicka reaction
as a promising blood marker of head and neck malignant tumours. Int
J Electrochem Sci. 7:1767–1784. 2012.
|
|
94.
|
Sochor J, Hynek D, Krejcova L, et al:
Study of metallothionein role in spinocellular carcinoma tissues of
head and neck tumours using Brdicka reaction. Int J Electrochem
Sci. 7:2136–2152. 2012.
|
|
95.
|
Masarik M, Cernei N, Majzlik P, et al:
Level of metallothionein, glutathione and heat-stable proteins in
tumours from patients with head and neck cancer. Int J Mol Med.
26:S462010.
|
|
96.
|
Dutsch-Wicherek M, Lazar A, Tomaszewska R,
Kazmierczak W and Wicherek L: Analysis of metallothionein and
vimentin immunoreactivity in pharyngeal squamous cell carcinoma and
its microenvironment. Cell Tissue Res. 352:341–349. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
97.
|
Jayasurya A, Bay BH, Yap WM, Tan NG and
Tan BKH: Proliferative potential in nasopharyngeal carcinoma:
correlations with metallothionein expression and tissue zinc
levels. Carcinogenesis. 21:1809–1812. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
98.
|
Dutsch-Wicherek M, Popiela TJ, Klimek M,
et al: Metallothionein stroma reaction in tumor adjacent healthy
tissue in head and neck squamous cell carcinoma and breast
adenocarcinoma. Neuroendocrinol Lett. 26:567–574. 2005.PubMed/NCBI
|
|
99.
|
Babula P, Kohoutkova V, Opatrilova R,
Dankova I, Masarik M and Kizek R: Pharmaceutical importance of zinc
and metallothionein in cell signalling. Chim Oggi-Chem Today.
28:18–21. 2010.
|
|
100.
|
Gumulec J, Masarik M, Krizkova S, et al:
Insight to physiology and pathology of zinc(II) ions and their
actions in breast and prostate carcinoma. Curr Med Chem.
18:5041–5051. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101.
|
Meplan C, Richard MJ and Hainaut P:
Metalloregulation of the tumor suppressor protein p53: zinc
mediates the renaturation of p53 after exposure to metal chelators
in vitro and in intact cells. Oncogene. 19:5227–5236. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
102.
|
Hainaut P and Mann K: Zinc binding and
redox control of p53 structure and function. Antioxid Redox Signal.
3:611–623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
103.
|
Pintus SS, Ivanisenko NV, Demenkov PS, et
al: The substitutions G245C and G245D in the
Zn2+-binding pocket of the p53 protein result in
differences of conformational flexibility of the DNA-binding
domain. J Biomol Struct Dyn. 31:78–86. 2013.PubMed/NCBI
|
|
104.
|
Tohyama C, Suzuki JS, Hemelraad J,
Nishimura N and Nishimura H: Induction of metallothionein and its
localization in the nucleus of rat hepatocytes after
partial-hepatectomy. Hepatology. 18:1193–1201. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
105.
|
Tsujikawa K, Imai T, Kakutani M, et al:
Localization of metallothionein in nuclei of growing primary
cultured adult-rat hepatocytes. FEBS Lett. 283:239–242. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
106.
|
Nartey NO, Banerjee D and Cherian MG:
Immunohistochemical localization of metallothionein in cell-nucleus
and cytoplasm of fetal human-liver and kidney and its changes
during development. Pathology. 19:233–238. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
107.
|
Banerjee D, Onosaka S and Cherian MG:
Immunohistochemical localization of metallothionein in cell-nucleus
and cytoplasm of rat-liver and kidney. Toxicology. 24:95–105. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
108.
|
Tohno Y, Tohno S, Minami T, et al:
Bindings of metallothionein to supranucleosomal fibers in mouse
pancreatic nuclei after induction by 4-aminopyrazolo [3,4-d]
pyrimidine. Cell Mol Biol. 42:1121–1127. 1996.PubMed/NCBI
|
|
109.
|
Sunderman FW, GrbacIvankovic S, Plowman MR
and Davis M: Zn2+-induction of metallothionein in
myotomal cell nuclei during somitogenesis of Xenopus laevis.
Mol Reprod Dev. 43:444–451. 1996.
|
|
110.
|
Bernard X, Robinson P, Nomine Y, et al:
Proteasomal degradation of p53 by human papillomavirus E6
oncoprotein relies on the structural integrity of p53 core domain.
PLoS One. 6:1–10. 2011. View Article : Google Scholar : PubMed/NCBI
|
